(Q54025029)

http://europepmc.org/abstract/MED/27137693

23 May 2018

review article

1 reference

title

[Alpha-Radioimmunotherapy: principle and relevance in anti-tumor immunity]. (English)

1 reference

http://europepmc.org/abstract/MED/27137693

23 May 2018

author

Joelle Gaschet

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137693%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

author name string

Jérémie Ménager

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137693%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Jean-Baptiste Gorin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137693%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Nolwenn Fichou

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137693%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Sébastien Gouard

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137693%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Alfred Morgenstern

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137693%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Frank Bruchertseifer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137693%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

François Davodeau

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137693%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Françoise Kraeber-Bodéré

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137693%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Michel Chérel

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137693%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Yannick Guilloux

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137693%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

language of work or name

French

0 references

publication date

1 April 2016

1 reference

http://europepmc.org/abstract/MED/27137693

23 May 2018

published in

médecine/sciences

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137693%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137693%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137693%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

page(s)

362-369

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137693%20AND%20SRC:MED&resulttype=core&format=json

Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.

5 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

131I-tositumomab therapy as initial treatment for follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Radionuclide therapy in neuroendocrine tumours: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Alpha emitter radium-223 and survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Radionuclide antibody-conjugates, a targeted therapy towards cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Targeted alpha-therapy: past, present, future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Clinical radioimmunotherapy--the role of radiobiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Molecular pathways: targeted α-particle radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p.

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Radiation oncology: a century of achievements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Trial Watch: Anticancer radioimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Activation of local and systemic anti-tumor immune responses by ablation of solid tumors with intratumoral electrochemical or alpha radiation treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Tumor ablation by intratumoral Ra-224-loaded wires induces anti-tumor immunity against experimental metastatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Antitumor immunity induced after α irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Immunogenic cell death in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Combining radiotherapy and immunotherapy: a revived partnership

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Combining radiotherapy and cancer immunotherapy: a paradigm shift

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014

Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20163204014